Patents Assigned to Celgene Corporation
  • Patent number: 11149007
    Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, L, V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 19, 2021
    Assignee: Celgene Corporation
    Inventors: Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
  • Publication number: 20210309966
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Application
    Filed: March 12, 2021
    Publication date: October 7, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Bitao LIANG, Wei LIU
  • Patent number: 11136306
    Abstract: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Celgene Corporation
    Inventors: Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller
  • Publication number: 20210299175
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: March 5, 2021
    Publication date: September 30, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • Patent number: 11129821
    Abstract: Provided herein are lyophilized formulations of 2-(4-chlorophenyl)—N—((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: September 28, 2021
    Assignee: Celgene Corporation
    Inventors: Ho-Wah Hui, Yu Pu
  • Patent number: 11130820
    Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: September 28, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Bitao Liang, Tianjian Li
  • Patent number: 11116782
    Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 14, 2021
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 11096940
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene Corporation
    Inventors: Ellen Filvaroff, Kristen M. Hege, Shaoyi Li
  • Publication number: 20210254003
    Abstract: In one embodiment, provided herein are cells, e.g., T cells expressing receptors that that cause a cell expressing the receptors to home to specific anatomical regions, e.g., the B cell zone of lymph nodes, the gastrointestinal tract, or the skin. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Application
    Filed: September 30, 2020
    Publication date: August 19, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Bitao LIANG, Wei LIU, Tianjian LI
  • Publication number: 20210254000
    Abstract: Provided herein are methods for producing engineered T cells that express a recombinant receptor, such as for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion, in which one or more steps is carried out in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, cultivation is performed in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, the provided methods produce genetically engineered T cells with improved persistence and/or anti-tumor activity in vivo.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 19, 2021
    Applicants: Juno Therapeutics, Inc., Celgene Corporation
    Inventors: Archana BRAHMANDAM, Lucas James THOMPSON, Deborah MORTENSEN, Ellen FILVAROFF
  • Publication number: 20210230136
    Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate are also disclosed.
    Type: Application
    Filed: January 14, 2021
    Publication date: July 29, 2021
    Applicant: Celgene Corporation
    Inventor: Jerry Lee Atwood
  • Patent number: 11053199
    Abstract: Provided herein are crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate. Pharmaceutical compositions comprising crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are also disclosed.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: July 6, 2021
    Assignees: Celgene Corporation, Abide Therapeutics, Inc.
    Inventors: Lianfeng Huang, Nancy Tsou, Nicole Suzanne White, Jun Xu, Qun Zhang
  • Patent number: 11028093
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: June 8, 2021
    Assignees: ARRAY BIOPHARMA INC., CELGENE CORPORATION
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
  • Publication number: 20210163890
    Abstract: Provided herein are methods of generating T cells, e.g., cytotoxic T lymphocytes starting from peripheral blood mononuclear cells without a separate step of generating and isolating antigen-presenting cells, and with a single round of antigen stimulation. Also provided herein are methods of using said cytotoxic T lymphocytes, for example, to treat cancer and/or viral infection.
    Type: Application
    Filed: December 29, 2016
    Publication date: June 3, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Bitao LIANG, Xiaohua LU, Wei LIU, Kathy E. KARASCIEWICZ-MENDEZ, Christopher WIWI, Kruti SHAH
  • Patent number: 11013723
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 11014897
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Lianfeng Huang, Daozhong Zou
  • Patent number: 11014940
    Abstract: Provided herein are thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV). Also provided herein are uses of these thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV), pharmaceutical compositions and formulations in the treatment of various diseases, including but not limited to diseases or disorders associated with an activated immune system (e.g., multiple sclerosis and psoriasis).
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: John Fitzgerald Traverse, Sanjeevani Ghone, Fu-An Kang, Francisco Velazquez
  • Publication number: 20210128619
    Abstract: Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicants: CELGENE CORPORATION, JUNO THERAPEUTICS, INC., BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Timothy CAMPBELL, Ronald HAUSE, Kristen HEGE, Yue JIANG, Shari KAISER, Ethan THOMPSON, Jaymes FULLER, Nathan MARTIN, Rong LIU, Justine DELL'ARINGA
  • Patent number: 10996215
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 4, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle Macbeth
  • Publication number: 20210116454
    Abstract: A method of identifying a subject having a hematological cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the hematological cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 22, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Maria Soraya Carrancio ANTON, Celia Fontanillo FONTANILLO, Shailaja KASIBHATLA, Antonia LOPEZ-GIRONA, Gang LU, Kai WANG